Pfizer Results May Temper Efforts for Shakeup Demanded by Activist Investor
Pfizer beat third-quarter profit and sales forecasts and raised its guidance on strong sales of its COVID-19 treatment.
Pfizer Exceeds Wall Street’s Q3 Expectations Amid Activist Investor Pressure
CEO Albert Bourla, who is under attack from activist investor Starboard Value, got a much-needed victory on Tuesday as Pfizer reported that third-quarter revenue and adjusted profit beat the analysts’ consensus.
Pfizer raises full-year guidance by $1.5 billion amid activist investor pressure
Pfizer ( PFE) raised its full-year guidance by $1.5 billion and posted strong third quarter earnings Tuesday. The company now expects between $61 billion and $64 billion in revenue for the year and raised its outlook for adjusted earnings to $2.75 to $2.95 per share.
Pfizer's Strategic Pivot: Navigating Challenges Amid Investor Pressure
Pfizer CEO Albert Bourla addresses Wall Street, defending the drugmaker's turnaround strategy amidst pressure from activist hedge fund Starboard Value. Despite higher-than-expected profits from COVID-19 drug sales,
Pfizer CEO defends turnaround strategy as activist pressures management
By Michael Erman and Bhanvi Satija (Reuters) -Pfizer CEO Albert Bourla, under pressure from activist hedge fund Starboard Value, made his case to Wall Street on Tuesday that the drugmaker's turnaround is succeeding after it reported a higher-than-expected profit due to strong sales of COVID-19 treatment Paxlovid.
Pfizer CEO: The activist investors are 'too late'
Pfizer had a "constructive" meeting with activist investor Starboard Value last week and spoke publicly about it for the first time on Tuesday.
Pfizer CEO Defends Record Against Activist Attack
Pfizer shares have performed abysmally in recent years, as the company has failed to win investor confidence ahead of a wave of patent expirations coming by the end of the decade.
Pfizer CEO, Under Fire, Will Do ‘Whatever It Takes’ to Grow
Pfizer Inc. Chief Executive Officer Albert Bourla said he’ll do “whatever it takes” to keep profits growing, including further cost cuts, as he seeks to fend off allegations of mismanagement from activist investor Starboard Value LP.
Pfizer CEO Albert Bourla goes one-on-one with Jim Cramer
Pfizer Chairman and CEO Albert Bourla joins 'Mad Money' host Jim Cramer to talk quarterly results, what's in the pipeline, ...
Pfizer's Oncology Triumphs Keep Investors Hooked Amid Market Volatility
Despite today's fall in Pfizer's share price, it beat my and Wall Street analysts' expectations for Q3 by a large margin. See ...
Pfizer is getting another COVID-19 sales boost
Pfizer (PFE) reported its third-quarter earnings on Tuesday, beating Wall Street expectations and its raising its full-year ...
Pfizer CEO says he welcomes good ideas as Starboard ups pressure on company
Pfizer reported an earnings beat Tuesday morning and raised its full-year outlook, seeing strength in sales of its Covid ...
Why is Pfizer stock falling after Q3 results?
Pfizer (PFE) stock fell even as the company beat forecasts with its Q3 results and increased its full-year outlook.Find out ...
devdiscourse14h
Pfizer's Paxlovid Success: A Glimmer Amidst Investor Scrutiny
Pfizer reported higher-than-expected profit due to strong sales of COVID-19 treatment Paxlovid. Despite this success, the ...
BioPharma Dive16h
Pfizer answers Starboard challenge with beat-and-raise quarter
Company CEO Albert Bourla said Pfizer would consider “any good ideas” that create value, but argued it has already made ...
Pfizer (PFE) Q3 2024 Earnings Call Transcript
Good day, everyone, and welcome to Pfizer's third quarter 2024 earnings conference call. Today's call is being recorded. At ...